Keywords: Tumors (Pre-Treatment), Tumors, Glioma, Cystathionine, Glutathione, Glutamate, Cysteine
Motivation: The cysteine metabolic pathway has been previously shown to be involved in the pathogenesis of gliomas and upregulated in glioblastomas relative to lower-grade gliomas.
Goal(s): The aim of this study was to investigate cysteine metabolism in glioma patients in vivo.
Approach: Edited 1H-MRS targeting cystathionine was performed in twenty-nine patients with lesions radiographically consistent with gliomas.
Results: Cystathionine, glutamate, and glutathione were found to be higher in grade IV than in grade II/III tumors. Cystathionine and glutamate concentrations were also positively correlated with glutathione concentrations.
Impact: The measurement of dysregulated cysteine metabolism by 1H-MRS could provide a non-invasive biomarker for monitoring treatments that target this pathway, including cysteine depletion. High levels of cystathionine in the absence of 2HG could be a marker of IDH-wildtype glioblastoma.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords